17:27 , Oct 12, 2018 |  BC Week In Review  |  Clinical News

Despite manufacturing concern, Acacia still expects 1H19 launch for PONV therapy

Acacia Pharma Group plc (Euronext:ACPH) said FDA raised a concern related to manufacturing deficiencies in a complete response letter issued for an NDA seeking approval of Barhemsys amisulpride to treat and prevent postoperative nausea and...
18:21 , Oct 8, 2018 |  BC Extra  |  Company News

Despite manufacturing concern, Acacia still expects 1H19 launch for PONV therapy

Acacia Pharma Group plc (Euronext:ACPH) said FDA raised a concern related to manufacturing deficiencies in a complete response letter issued Monday for an NDA seeking approval of Barhemsys amisulpride to treat and prevent postoperative nausea...
14:42 , Apr 6, 2018 |  BC Week In Review  |  Clinical News

Allergan's cariprazine meets again in Phase III for bipolar I depression

Allergan plc (NYSE:AGN) and Gedeon Richter plc (Budapest:RICHTER) said low-dose cariprazine met the primary endpoint in the Phase III RGH-MD-53 trial to treat bipolar I depression. Allergan reiterated its plan to submit an sNDA to...
20:55 , Apr 3, 2018 |  BC Extra  |  Clinical News

Allergan's cariprazine meets again in Phase III for bipolar I depression

Allergan plc (NYSE:AGN) and Gedeon Richter plc (Budapest:RICHTER) said low-dose cariprazine met the primary endpoint in the Phase III RGH-MD-53 trial to treat bipolar I depression. Allergan reiterated its plan to submit an sNDA to...
18:10 , Mar 9, 2018 |  BC Week In Review  |  Financial News

Acacia raises €40M in IPO

Acacia Pharma Group plc (Euronext:ACPH) raised €40 million ($49.3 million) on March 2 through the sale of 11.1 million shares at €3.60 in an IPO underwritten by Bank Degroof Petercam NV/SA and RBC Europe. The...
20:14 , Mar 2, 2018 |  BC Extra  |  Financial News

Acacia raises €40M in IPO

Acacia Pharma Group plc (Euronext:ACPH) raised €40 million ($49.3 million) through the sale of 11.1 million shares at €3.60 in an IPO underwritten by Bank Degroof Petercam NV/SA and RBC Europe. The price values the...
21:34 , Jan 5, 2018 |  BC Week In Review  |  Financial News

Neurogastrx raises $45M series A

Gastrointestinal company Neurogastrx Inc. (Boston, Mass.) raised $45 million on Jan. 4 in a tranched series A round co-led by new investors 5AM Ventures, OrbiMed Advisors and venBio. The GI company also hired Jim O'Mara...
17:38 , Jan 5, 2018 |  BC Week In Review  |  Clinical News

FDA reviewing Acacia's PONV therapy

Acacia Pharma Group Ltd. (Cambridge, U.K.) said FDA accepted for review an NDA for Baremsis amisulpride (formerly APD421), alone and in combination with other antiemetics, as treatment and prophylaxis for postoperative nausea and vomiting (PONV)....
23:14 , Jan 4, 2018 |  BC Extra  |  Financial News

GI company Neurogastrx in $45M series A

Neurogastrx Inc. (Boston, Mass.) raised $45 million in a tranched series A round co-led by new investors 5AM Ventures, OrbiMed Advisors and venBio. The GI company also hired Jim O'Mara as CEO and appointed OrbiMed’s...
08:03 , Jan 4, 2018 |  BC Extra  |  Company News

FDA reviewing Acacia's PONV therapy

Acacia Pharma Group Ltd. (Cambridge, U.K.) said FDA accepted for review an NDA for Baremsis amisulpride (formerly APD421), alone and in combination with other antiemetics, as treatment and prophylaxis for postoperative nausea and vomiting. The...